Fibroblastes associés au cancer : Questions médicales fréquentes
Nom anglais: Cancer-Associated Fibroblasts
Descriptor UI:D000072645
Tree Number:A11.329.228.105
Termes MeSH sélectionnés :
REM Sleep Behavior Disorder
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Fibroblastes associés au cancer : Questions médicales les plus fréquentes",
"headline": "Fibroblastes associés au cancer : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Fibroblastes associés au cancer : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-14",
"dateModified": "2025-05-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Fibroblastes associés au cancer"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Fibroblastes",
"url": "https://questionsmedicales.fr/mesh/D005347",
"about": {
"@type": "MedicalCondition",
"name": "Fibroblastes",
"code": {
"@type": "MedicalCode",
"code": "D005347",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.329.228"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Fibroblastes associés au cancer",
"alternateName": "Cancer-Associated Fibroblasts",
"code": {
"@type": "MedicalCode",
"code": "D000072645",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Atsushi Enomoto",
"url": "https://questionsmedicales.fr/author/Atsushi%20Enomoto",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan. enomoto@iar.nagoya-u.ac.jp."
}
},
{
"@type": "Person",
"name": "Susan L Woods",
"url": "https://questionsmedicales.fr/author/Susan%20L%20Woods",
"affiliation": {
"@type": "Organization",
"name": "Adelaide Medical School, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia."
}
},
{
"@type": "Person",
"name": "Masahide Takahashi",
"url": "https://questionsmedicales.fr/author/Masahide%20Takahashi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan."
}
},
{
"@type": "Person",
"name": "Daniel L Worthley",
"url": "https://questionsmedicales.fr/author/Daniel%20L%20Worthley",
"affiliation": {
"@type": "Organization",
"name": "Adelaide Medical School, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia. Dan.Worthley@sahmri.com."
}
},
{
"@type": "Person",
"name": "Chencheng Han",
"url": "https://questionsmedicales.fr/author/Chencheng%20Han",
"affiliation": {
"@type": "Organization",
"name": "Department of Thoracic Surgery, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "REM Behavior Disorder: Implications for PD Therapeutics.",
"datePublished": "2023-10-13",
"url": "https://questionsmedicales.fr/article/37831394",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11910-023-01310-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neurofilament light chain and cardiac MIBG uptake as predictors for phenoconversion in isolated REM sleep behavior disorder.",
"datePublished": "2023-05-26",
"url": "https://questionsmedicales.fr/article/37233802",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00415-023-11785-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cerebellar Volume Reduction in Patients with Isolated REM Sleep Behavior Disorder: Evidence of a Potential Role of the Cerebellum.",
"datePublished": "2023-08-01",
"url": "https://questionsmedicales.fr/article/37527632",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000533297"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cognitive and motor profiles as prodromal markers in predicting phenoconversion and phenotype in isolated REM sleep behavior disorder.",
"datePublished": "2023-10-28",
"url": "https://questionsmedicales.fr/article/37925853",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.sleep.2023.10.027"
}
},
{
"@type": "ScholarlyArticle",
"name": "Misfolded α-Synuclein Assessment in the Skin and CSF by RT-QuIC in Isolated REM Sleep Behavior Disorder.",
"datePublished": "2023-03-17",
"url": "https://questionsmedicales.fr/article/36931726",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1212/WNL.0000000000207147"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Cellules",
"item": "https://questionsmedicales.fr/mesh/D002477"
},
{
"@type": "ListItem",
"position": 3,
"name": "Cellules du tissu conjonctif",
"item": "https://questionsmedicales.fr/mesh/D003239"
},
{
"@type": "ListItem",
"position": 4,
"name": "Fibroblastes",
"item": "https://questionsmedicales.fr/mesh/D005347"
},
{
"@type": "ListItem",
"position": 5,
"name": "Fibroblastes associés au cancer",
"item": "https://questionsmedicales.fr/mesh/D000072645"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Fibroblastes associés au cancer - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Fibroblastes associés au cancer",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Fibroblastes associés au cancer",
"description": "Comment identifier les CAF dans une tumeur ?\nQuels tests sont utilisés pour détecter les CAF ?\nLes CAF sont-ils visibles par imagerie ?\nPeut-on quantifier les CAF dans un échantillon ?\nLes CAF peuvent-ils être distingués des fibroblastes normaux ?",
"url": "https://questionsmedicales.fr/mesh/D000072645?mesh_terms=REM+Sleep+Behavior+Disorder&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Fibroblastes associés au cancer",
"description": "Quels symptômes sont liés aux CAF ?\nLes CAF affectent-ils la douleur tumorale ?\nLes CAF sont-ils impliqués dans la fatigue liée au cancer ?\nLes CAF influencent-ils les symptômes de métastases ?\nLes CAF sont-ils liés à des symptômes spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D000072645?mesh_terms=REM+Sleep+Behavior+Disorder&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Fibroblastes associés au cancer",
"description": "Peut-on prévenir la formation de CAF ?\nLes facteurs environnementaux influencent-ils les CAF ?\nL'alimentation joue-t-elle un rôle dans la prévention des CAF ?\nL'exercice physique peut-il réduire les CAF ?\nLes dépistages précoces aident-ils à prévenir les CAF ?",
"url": "https://questionsmedicales.fr/mesh/D000072645?mesh_terms=REM+Sleep+Behavior+Disorder&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Fibroblastes associés au cancer",
"description": "Comment cibler les CAF dans le traitement du cancer ?\nLes CAF peuvent-ils être une cible pour l'immunothérapie ?\nQuels médicaments affectent les CAF ?\nLes CAF peuvent-ils influencer la résistance aux traitements ?\nY a-t-il des essais cliniques sur les CAF ?",
"url": "https://questionsmedicales.fr/mesh/D000072645?mesh_terms=REM+Sleep+Behavior+Disorder&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Fibroblastes associés au cancer",
"description": "Quels sont les risques associés aux CAF ?\nLes CAF sont-ils liés à des complications post-chirurgicales ?\nLes CAF peuvent-ils affecter la qualité de vie ?\nLes CAF sont-ils impliqués dans des complications métastatiques ?\nLes CAF peuvent-ils influencer la survie des patients ?",
"url": "https://questionsmedicales.fr/mesh/D000072645?mesh_terms=REM+Sleep+Behavior+Disorder&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Fibroblastes associés au cancer",
"description": "Quels facteurs augmentent le risque de CAF ?\nL'âge influence-t-il le développement des CAF ?\nLes antécédents familiaux de cancer sont-ils un facteur de risque ?\nLe stress peut-il influencer les CAF ?\nLes infections chroniques sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D000072645?mesh_terms=REM+Sleep+Behavior+Disorder&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les CAF dans une tumeur ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les CAF peuvent être identifiés par des marqueurs spécifiques comme FAP et α-SMA."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les CAF ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunohistochimie et la cytométrie en flux sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les CAF sont-ils visibles par imagerie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les CAF ne sont pas directement visibles, mais leur effet sur la tumeur peut être évalué par imagerie."
}
},
{
"@type": "Question",
"name": "Peut-on quantifier les CAF dans un échantillon ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des techniques comme la PCR et l'analyse de l'expression génique permettent leur quantification."
}
},
{
"@type": "Question",
"name": "Les CAF peuvent-ils être distingués des fibroblastes normaux ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les CAF présentent des caractéristiques morphologiques et fonctionnelles distinctes."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux CAF ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les CAF ne causent pas de symptômes directs, mais influencent la progression tumorale."
}
},
{
"@type": "Question",
"name": "Les CAF affectent-ils la douleur tumorale ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les CAF peuvent moduler la douleur en influençant l'inflammation et la croissance tumorale."
}
},
{
"@type": "Question",
"name": "Les CAF sont-ils impliqués dans la fatigue liée au cancer ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, les CAF peuvent contribuer à la fatigue en favorisant la progression tumorale."
}
},
{
"@type": "Question",
"name": "Les CAF influencent-ils les symptômes de métastases ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les CAF peuvent favoriser la migration des cellules tumorales et donc les symptômes de métastases."
}
},
{
"@type": "Question",
"name": "Les CAF sont-ils liés à des symptômes spécifiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils ne causent pas de symptômes spécifiques, mais leur présence peut aggraver l'état général du patient."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la formation de CAF ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention des CAF est complexe, mais un mode de vie sain peut réduire le risque de cancer."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils les CAF ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs comme l'inflammation chronique et le tabagisme peuvent favoriser les CAF."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention des CAF ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut aider à réduire le risque de cancer et donc de CAF."
}
},
{
"@type": "Question",
"name": "L'exercice physique peut-il réduire les CAF ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut diminuer l'inflammation et potentiellement réduire les CAF."
}
},
{
"@type": "Question",
"name": "Les dépistages précoces aident-ils à prévenir les CAF ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les dépistages précoces peuvent aider à détecter le cancer avant que les CAF ne se développent."
}
},
{
"@type": "Question",
"name": "Comment cibler les CAF dans le traitement du cancer ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées et des inhibiteurs de signalisation sont en développement pour cibler les CAF."
}
},
{
"@type": "Question",
"name": "Les CAF peuvent-ils être une cible pour l'immunothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les CAF peuvent être ciblés pour améliorer l'efficacité de l'immunothérapie anticancéreuse."
}
},
{
"@type": "Question",
"name": "Quels médicaments affectent les CAF ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les inhibiteurs de TGF-β et les agents anti-fibrotiques peuvent affecter les CAF."
}
},
{
"@type": "Question",
"name": "Les CAF peuvent-ils influencer la résistance aux traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les CAF peuvent contribuer à la résistance aux traitements en modifiant le microenvironnement tumoral."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques sur les CAF ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs essais cliniques explorent des thérapies ciblant les CAF dans divers cancers."
}
},
{
"@type": "Question",
"name": "Quels sont les risques associés aux CAF ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les CAF peuvent favoriser la progression tumorale et la résistance aux traitements."
}
},
{
"@type": "Question",
"name": "Les CAF sont-ils liés à des complications post-chirurgicales ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les CAF peuvent influencer la cicatrisation et augmenter le risque de récidive."
}
},
{
"@type": "Question",
"name": "Les CAF peuvent-ils affecter la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, leur présence peut aggraver les symptômes et diminuer la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Les CAF sont-ils impliqués dans des complications métastatiques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les CAF peuvent faciliter la migration des cellules tumorales vers d'autres organes."
}
},
{
"@type": "Question",
"name": "Les CAF peuvent-ils influencer la survie des patients ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la présence de CAF est souvent associée à un pronostic défavorable dans plusieurs cancers."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de CAF ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'inflammation chronique, le tabagisme et l'obésité sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le développement des CAF ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de développer des CAF augmente avec l'âge en raison de changements cellulaires."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux de cancer sont-ils un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux peuvent augmenter le risque de développer des CAF."
}
},
{
"@type": "Question",
"name": "Le stress peut-il influencer les CAF ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter le microenvironnement tumoral et favoriser les CAF."
}
},
{
"@type": "Question",
"name": "Les infections chroniques sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections chroniques peuvent contribuer à l'inflammation et à la formation de CAF."
}
}
]
}
]
}
Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia that occurs during REM sleep, characterized by REM sleep without atonia (RSWA) and dream enactment behavior (DEB). RBD is associa...
Recent research recognizes RBD as a prodromal marker of PD, resulting in expansion of basic science and clinical investigations of RBD. Current basic science research investigates the pathophysiology ...
Isolated rapid-eye-movement (REM) sleep behavior disorder (iRBD) is considered as a prodromal stage of either multiple system atrophy (MSA) or Lewy body disease (LBD; Parkinson's disease and dementia ...
Forty patients with iRBD were enrolled between April 2018 and October 2019 and prospectively followed every 3 months to determine phenoconversion to either MSA or LBD. Plasma NfL levels were measured ...
Patients were followed for a median of 2.92 years. Four patients converted to MSA and 7 to LBD. Plasma NfL level at baseline was significantly higher in future MSA-converters (median 23.2 pg/mL) when ...
Plasma NfL and cardiac MIBG uptake may be useful biomarkers in predicting phenoconversion of iRBD. Elevated plasma NfL levels may suggest imminent phenoconversion to MSA, whereas low cardiac MIBG upta...
In this study, we aimed to investigate changes in the total cerebellar volume, subdivisions of the cerebellar volume, and intrinsic cerebellar network in patients with isolated rapid eye movement (REM...
We enrolled patients with newly diagnosed iRBD and healthy controls who had no structural lesions according to their brain MRI. All participants underwent three-dimensional T1-weighted imaging. We obt...
In total, we enrolled 43 patients with iRBD and 47 healthy controls. Total cerebellar volume in patients with iRBD was lower than that in the healthy controls (8.4637 vs. 9.0863%, p = 0.0001). There w...
We found decreased total cerebellar volumes and subdivisions of the cerebellar volume, particularly in the right and left lobule VIIB, in patients with iRBD compared to healthy controls. The present r...
To determine the clinical markers based on cognitive and motor profiles in predicting phenoconverion and phenotype in isolated rapid eye movement sleep behavior disorder (iRBD)....
45 iRBD patients and 25 healthy controls were included in the follow-up study. All participates received comprehensive evaluations of cognitive, motor and autonomic function at baseline. Positive phen...
21 iRBD patients displayed phenoconversion in a mean follow-up of 2.9 ± 1.6 years, with 14 presenting motor phenotype and 7 cognitive phenotype. In iRBD, visuospatial, memory, attention-executive func...
In iRBD, the attention-executive and motor function served as optimum combined markers in predicting phenoconversion and motor phenotype, whereas the attention-executive function performed best in pre...
Real-time quaking-induced conversion (RT-QuIC) assay detects misfolded α-synuclein (AS) in the skin and CSF of patients with the synucleinopathies Parkinson disease and dementia with Lewy bodies. Isol...
This was a cross-sectional study where consecutive patients with polysomnographic-confirmed IRBD and age-matched controls without RBD underwent skin biopsy and lumbar puncture the same day. Three-mill...
We recruited 91 patients with IRBD and 41 controls. In the skin, sensitivity to detect AS was 76.9% (95% CI 66.9-85.1), specificity 97.6% (95% CI 87.1-99.9) positive predictive value 98.6% (95% CI 91....
Our study in IRBD shows that (1) RT-QuIC detects AS in the skin and CSF with similar high sensitivity, specificity, and agreement, (2) AS RT-QuIC positivity is associated with supportive features and ...
This study provides Class III evidence that RT-QuIC-detected AS in the skin and CSF distinguishes patients with IRBD from controls....
This study aimed to correlate REM sleep without atonia (RSWA) and neuropsychological data in patients with idiopathic/isolated REM sleep behaviour disorder (iRBD) and those with RBD associated with Pa...
Previous studies have shown that rapid eye movement sleep without atonia during polysomnography can predict the risk of phenoconversion to neurodegenerative disease in patients with isolated rapid eye...
To evaluate the prevalence of REM sleep behavior disorder (RBD) and its possible prodromal conditions, isolated dream enactment behavior (DEB) and isolated REM without atonia (RWA), in a general popul...
From a population-based prospective cohort in Korea, 1,075 participants (age 60.1 ± 7.0 years; range 50-80 years; men 53.7%) completed the RBD screening questionnaire (RBDSQ), a structured telephone i...
RBD was diagnosed in 20 participants, isolated RWA in 133 participants, and isolated DEB in 48 participants. Sex and DEB frequency-adjusted prevalence of RBD was 1.4% (95% CI 1.0%-1.8%), isolated RWA ...
This study provides prevalence estimates of RBD and its possible prodromal conditions based on a structured telephone interview and RWA measurement on PSG from the general population....
Rapid-eye movement (REM) sleep behavior disorder (RBD), enactment of dreams during REM sleep, is an early clinical symptom of alpha-synucleinopathies and defines a more severe subtype. The genetic bac...
The microbiota-gut-brain axis has been suggested to play an important role in Parkinson's disease (PD). Here we performed a cross-sectional study to profile gut microbiota across early PD, REM sleep b...